We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
+1.2%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$1.79B
AUM Growth
-$552M
Cap. Flow
-$341M
Cap. Flow %
-19.04%
Top 10 Hldgs %
44.27%
Holding
146
New
11
Increased
19
Reduced
12
Closed
17

Top Buys

Rank Stock Value
1
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$32.9M
2
AGEN
Agenus
AGEN
+$27.2M
3
RVMD icon
Revolution Medicines
RVMD
+$21.3M
4
KYMR icon
Kymera Therapeutics
KYMR
+$13.3M
5
VOR icon
Vor Biopharma
VOR
+$11.5M

Top Sells

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$53M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$47.9M
3
BLU
BELLUS Health Inc.
BLU
+$21.4M
4
ONC
BeOne Medicines Ltd
ONC
+$9.17M
5
EQRX
EQRx, Inc. Common Stock
EQRX
+$7.88M

Sector Composition

Rank Sector Weight
1 Healthcare 92.03%
2 Consumer Discretionary 3.74%
3 Real Estate 0.39%
4 Financials 0.33%
5 Industrials 0.18%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LXRX icon
1
Lexicon Pharmaceuticals
LXRX
$1.03B
$171M 9.57%
89,778,234
– –
ONC
2
BeOne Medicines Ltd
ONC
$33.9B
$132M 7.37%
600,000
-50,000
-8% -$9.17M
MRTX
3
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$83M 4.64%
1,832,758
+507,758
+38% +$32.9M
SRRK icon
4
Scholar Rock
SRRK
$5.88B
$81.3M 4.54%
8,980,270
+230,236
+3% +$1.85M
CERE
5
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$59.9M 3.34%
1,900,000
-100,000
-5% -$2.82M
MORF
6
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$57.5M 3.21%
2,150,000
– –
WW
7
DELISTED
WW International
WW
$57.2M 3.19%
14,818,300
– –
SWTX
8
DELISTED
SpringWorks Therapeutics
SWTX
$52M 2.9%
2,000,000
-53,403
-3% -$1.32M
KYMR icon
9
Kymera Therapeutics
KYMR
$8.66B
$49.9M 2.79%
2,000,000
+500,000
+33% +$13.3M
FOLD
10
DELISTED
Amicus Therapeutics
FOLD
$48.8M 2.73%
4,000,000
– –
APLS
11
DELISTED
Apellis Pharmaceuticals
APLS
$46.5M 2.6%
900,000
-100,000
-10% -$5.3M
CYTK icon
12
Cytokinetics
CYTK
$10.6B
$45.8M 2.56%
1,000,000
– –
IGMS
13
DELISTED
IGM Biosciences
IGMS
$41.7M 2.33%
2,450,000
– –
AGEN
14
Agenus
AGEN
$276M
$34.8M 1.94%
738,775
+534,975
+263% +$27.2M
KRYS icon
15
Krystal Biotech
KRYS
$10.7B
$31.7M 1.77%
400,000
-100,000
-20% -$7.42M
BLU
16
DELISTED
BELLUS Health Inc.
BLU
$30.4M 1.7%
3,700,000
-2,300,000
-38% -$21.4M
KRTX
17
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$29.5M 1.65%
150,000
+25,000
+20% +$5.36M
KLRS
18
Kalaris Therapeutics
KLRS
$80.9M
$28.6M 1.6%
242,486
– –
SAGE
19
DELISTED
Sage Therapeutics
SAGE
$28.6M 1.6%
750,000
– –
VIGL
20
DELISTED
Vigil Neuroscience
VIGL
$28M 1.57%
2,243,352
-42,222
-2% -$518K
SEER icon
21
Seer Inc
SEER
$114M
$27.6M 1.54%
4,750,000
– –
FATE icon
22
Fate Therapeutics
FATE
$275M
$26.2M 1.46%
2,600,000
– –
RVMD icon
23
Revolution Medicines
RVMD
$38.5B
$23.8M 1.33%
+1,000,000
New +$21.3M
MRTX
24
CALL
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$22.7M 1.26%
+500,000
New +$32.4M
DNLI icon
25
Denali Therapeutics
DNLI
$3.79B
$22.2M 1.24%
800,000
+200,000
+33% +$5.95M
1
2 3 4 5

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
GA
GRS Advisors Chicago, Illinois $1.01B AUM 13.12% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $1.01B AUM 79.26% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
CT
Coastline Trust Providence, Rhode Island $1.01B AUM 22.57% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
PIM
Provident Investment Management Novi, Michigan $1.01B AUM 9.4% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Artal Group's Q4 2022 Portfolio in Review

As of Q4 2022, Artal Group held 146 positions worth $1.79B, down 24% from $2.34B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Artal Group withdrew a net $341M in Q4 2022, closing 17 positions and reducing 12 holdings. Its most notable exit was argenx, an estimated $53M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 78% a quarter earlier, followed by Consumer Discretionary and Real Estate.

Against the trend, Artal Group opened a new position in Revolution Medicines worth $23.8M.

  • Artal Group's largest Q4 2022 buy was Revolution Medicines: 1,000,000 shares worth $23.8M.
  • Artal Group added most to Mirati Therapeutics, Inc. Common Stock in Q4 2022, an estimated $32.9M increase.
  • Artal Group's biggest Q4 2022 reduction was BELLUS Health Inc., cutting an estimated $21.4M.
  • Artal Group fully exited argenx in Q4 2022, selling an estimated $53M.
  • Artal Group's ten largest holdings make up 44% of its $1.79B portfolio in Q4 2022.
  • Artal Group opened 11 new positions and closed 17 in Q4 2022.
  • Artal Group's portfolio value fell 24% quarter-over-quarter to $1.79B.

Based on Artal Group's 13F filing for Q4 2022, filed 13 Feb 2023.